Compare American States Water Company (AWR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American States Water Company vs Novo Nordisk A/S — how do they compare? American States Water Company trades at $84.92 (market cap $3.33B), while Novo Nordisk A/S trades at $50.28 (market cap $214.94B). The key difference: Novo Nordisk A/S is far larger — about 64.5× American States Water Company's market cap, and Novo Nordisk A/S pays the higher dividend (3.67%). Which is the better fit depends on your goals.
| AWR | NVO | |
|---|---|---|
Market Cap | $3.33B | $214.94B |
Sector | Utilities | Health |
52-Week High | $85.05 | $71.70 |
52-Week Low | $70.10 | $35.29 |
Enterprise Value | $4.24B | $233.91B |
Dividend Yield | 2.37% | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American States Water (AWR) trades at $85.05, up 0.64% today, with a bullish technical signal from moving averages and strong profitability metrics including a 19.66% net income margin. Recent news highlights its inclusion in TIME's America's Best Companies 2026 list and a completed $200 million ATM equity offering. The stock shows consistent dividend performance with a 71-year growth streak, though recent quarters saw mixed earnings results versus expectations.
Outlook remains stable with revenue growth to $679 million in 2026 and solid cash flow, but risks include regulatory pressures and interest rate sensitivity. Analysts are cautious with only 20% buy ratings. The stock offers defensive appeal but faces execution risks in a high-valuation environment.
Novo Nordisk (NVO) trades at $49.28, down 0.4% on the day, with strong technical momentum indicated by bullish moving averages and a neutral RSI near 63. The company demonstrates robust fundamentals with a P/E of 11.83, net income margin of 37.2%, and consistent earnings beats in recent quarters. Recent news highlights competitive strength in GLP-1 drugs, including Wegovy pill adoption outpacing Eli Lilly's offering.
Outlook remains positive given analyst consensus of 57.9% buy ratings and intrinsic value estimates near $90, though risks include prescription slowdown concerns and rising debt-to-asset ratios. The stock presents a growth opportunity in pharmaceuticals with manageable near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American States Water Company
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
